Oral PresentationsParallel Session: HCV Direct Acting Antivirals61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL
Parallel Session: HCV Direct Acting Antivirals
References (0)
Cited by (0)
Copyright © 2013 Elsevier B.V. and European Association for the Study of the Liver. All rights reserved.